Muitos novos agentes antivirais (por exemplo, beclabuvir, danoprevir, deleobuvir, faldaprevir, ravidasvir, ruzasvir, samatasvir, vedroprevir) estão sendo submetidos a ensaios clínicos para o tratamento da infecção por hepatite C.[97]Abutaleb A, Kottilil S. Vedroprevir in the management of hepatitis C virus infection. Expert Opin Investig Drugs. 2017 Dec;26(12):1399-402.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463276
http://www.ncbi.nlm.nih.gov/pubmed/29053394?tool=bestpractice.com
[98]Ahmed AM, Doheim MF, Mattar OM, et al. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. J Med Virol. 2018 May;90(5):907-18.
http://www.ncbi.nlm.nih.gov/pubmed/28892235?tool=bestpractice.com
[99]Meshram RJ, Kathwate GH, Gacche RN. Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections. Arch Virol. 2022 Mar;167(3):717-36.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795940
http://www.ncbi.nlm.nih.gov/pubmed/35089390?tool=bestpractice.com
O uso deste conteúdo está sujeito ao nosso aviso legal